Sign inJoin waitlistJoin the waitlist

Trent Hummel

Co-Medical Director · Cincinnati Children's Hospital Medical Center

Credentials: · · ·

History

Cincinnati Children's Hospital Medical Center
Present
University of Cincinnati Medical Center Inc.
Present
Cincinnati Children's Hospital Medical Center
Present

Pediatric Hematology Oncology
Cincinnati Children's Hospital Medical Center
2004–2007
Children’s Hospital Medical Center of Akron
2001–2004
University of Cincinnati College of Medicine
1997–2001
Eastern Mennonite University, Harrisburg, VA, 1997
1993–1997

Research

Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis
Neuro-Oncology · 2012 · 241 citations
Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics
Acta Neuropathologica Communications · 2016 · 131 citations
A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors
Clinical Cancer Research · 2019 · 83 citations

Maryam Fouladi
16 papers
Charles Stevenson
13 papers
Peter de Blank
12 papers
MD
Mariko Dewire-Schottmiller
11 papers
Ralph Salloum
11 papers · 5 as a fellow
James Leach
9 papers
Natasha Smiley
9 papers
Blaise Jones
8 papers
LC
Lionel Chow
8 papers
CF
Christine Fuller
6 papers
LM
Lili Miles
6 papers
Roger Packer
5 papers

Clinical trials

International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository
Principal investigator · Recruiting
Children's Hospital Medical Center, Cincinnati
2012–2047
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
Study chair · Terminated · Phase 2
Children's Hospital Medical Center, Cincinnati
2017–2024
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Site PI · Recruiting · Phase 2
Children's Oncology Group
2021–2029
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
Sub-investigator · Recruiting · Phase 2
Healx Limited
2025–2028